Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Document › Details

Sigma-Aldrich Corporation. (11/4/14). "Press Release: Sigma-Aldrich Completes Acquisition of Cell Marque". St. Louis.

Organisations Organisation Sigma-Aldrich Corporation (Nasdaq: SIAL)
  Group Merck (DE) (Group)
  Organisation 2 Cell Marque Corporation
  Group Merck (DE) (Group)
Products Product antibody, diagnostic
  Product 2 in vitro diagnostics (IVD)
Index term Index term Cell Marque–Sigma-Aldrich: investment, 201410–201411 acquisition €na of Cell Marque Corp by Sigma-Aldrich
Person Person Creasey, Theresa S. (Sigma-Aldrich 201411 VP Diagnostics + Testing of Applied Business Unit)

Sigma-Aldrich Corporation (NASDAQ: SIAL), a leading Life Science and High Technology company, announced it has completed its acquisition of Rocklin, California based Cell Marque Corporation, an industry-leading provider of in vitro diagnostic (IVD) antibody reagents and kits. The Company expects this acquisition to be neutral to mildly accretive to earnings per share in 2015. Terms of the transaction were not disclosed.

"We are pleased that Cell Marque is now part of Sigma-Aldrich. Our customers in clinical pathology and clinical laboratories worldwide will benefit from Cell Marque's extensive validation process of immunohistochemistry (IHC) diagnostic reagents, which, ultimately, leads to better patient management," said Theresa S. Creasey, Ph.D., Vice President, Diagnostics & Testing of Sigma-Aldrich's Applied Business Unit. "We welcome the Cell Marque team to Sigma-Aldrich and look forward to leveraging their vast scientific knowledge and expertise to augment our extensive capabilities in this emerging area."

Cell Marque is a well-recognized provider of diagnostic reagents widely used in IHC. With its high quality products and technical expertise, including validated, fit-for-purpose antibodies and IHC staining kits aimed at pathologists and clinicians focused on patient management, Cell Marque has earned a great deal of industry recognition. Cell Marque's products and scientific expertise will complement Sigma-Aldrich's workflow solutions aimed at IVD customers.

Cautionary statement: The foregoing release contains forward-looking statements that can be identified by terminology such as "expects," "will benefit," "leads to," "to augment" and "will complement" or similar expressions, or by expressed or implied discussions regarding potential future revenues or earnings. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that the acquisition of Cell Marque will achieve any particular levels of revenue or earnings in the future. In particular, management's expectations regarding the acquisition of Cell Marque could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's annual report on Form 10-K for the year ended December 31, 2013, as updated in its quarterly reports on Form 10-Q, on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma-Aldrich:

Sigma-Aldrich, a leading life science and high-technology company focused on enhancing human health and safety, manufactures and distributes 230,000 chemicals, biochemicals and other essential products to more than 1.4 million customers globally in research and applied labs as well as in industrial and commercial markets. With three distinct business units - Research, Applied and SAFC Commercial - Sigma-Aldrich is committed to enabling science to improve the quality of life. The company operates in 37 countries, has more than 9,000 employees worldwide and had sales of $2.7 billion in 2013. For more information about Sigma-Aldrich, please visit its website at

©2014 Sigma-Aldrich Co. LLC. All rights reserved. Sigma-Aldrich is a trademark of Sigma-Aldrich Co. LLC or its affiliates, registered in the U.S. and other countries.

Record changed: 2017-04-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Merck (DE) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top